<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00367497</url>
  </required_header>
  <id_info>
    <org_study_id>17-40</org_study_id>
    <nct_id>NCT00367497</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Salvage Chemotherapy (R-ESHAP) to Treat Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma</brief_title>
  <official_title>Phase 2 Study of Rituximab and ESHAP (Etoposide, Methylprednisolone, Cytarabine, and Cisplatin) in Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Keio University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Keio University</source>
  <brief_summary>
    <textblock>
      Aggressive non-Hodgkin's lymphoma is difficult to handle once it relapses or becomes&#xD;
      refractory to chemotherapy. Various second or third line chemotherapies, which are called&#xD;
      salvage chemotherapy, were developed without promising results. Improvement in efficacy by&#xD;
      adding relatively new agent, rituximab, to chemotherapy is now widely accepted in&#xD;
      non-Hodgkin's lymphoma. This study will test the safety and efficacy of adding rituximab to&#xD;
      existing salvage chemotherapy, ESHAP (R-ESHAP). Our aim is also to proceed to high-dose&#xD;
      chemotherapy with autologous hematopoietic stem cell transplantation after successful R-ESHAP&#xD;
      therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The stopping rule was applied because of low response rates.&#xD;
  </why_stopped>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of peripheral blood stem cell collection</measure>
  </secondary_outcome>
  <enrollment type="Actual">5</enrollment>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab, Etoposide, Methylprednisolone, Cytarabine, Cisplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of aggressive non-Hodgkin's lymphoma&#xD;
&#xD;
          -  Refractory to the first line chemotherapy or relapsed&#xD;
&#xD;
          -  Expression of CD20 on lymphoma cells&#xD;
&#xD;
          -  Measurable lesions on imaging studies&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Blood cell counts not reaching to 3,000/microliter for white blood cells, 7 g/dl for&#xD;
             hemoglobin, and 50,000/microliter for platelets without transfusion at the time of&#xD;
             registration&#xD;
&#xD;
          -  Circulating lymphoma cells equal to or more than 25,000/microliter&#xD;
&#xD;
          -  Hepatic dysfunction&#xD;
&#xD;
          -  Renal insufficiency&#xD;
&#xD;
          -  Cardiac dysfunction or arrhythmia&#xD;
&#xD;
          -  Sever infection (bacterial, viral)&#xD;
&#xD;
          -  CNS involvement&#xD;
&#xD;
          -  Other malignancies&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norihiro Awaya, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Keio University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Keio University School of Medicine</name>
      <address>
        <city>Tokyo</city>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <study_first_submitted>August 22, 2006</study_first_submitted>
  <study_first_submitted_qc>August 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2006</study_first_posted>
  <last_update_submitted>November 19, 2007</last_update_submitted>
  <last_update_submitted_qc>November 19, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2007</last_update_posted>
  <keyword>aggressive non-Hodgkin's lymphoma</keyword>
  <keyword>salvage chemotherapy</keyword>
  <keyword>rituximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Aggression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

